Daewoong Empowers Indonesian Healthcare with Advanced Stem Cell Therapy and GMP Facility
(Jakarta, 19 December 2024) Daewoong has emerged as a pioneer in Indonesia's stem cell therapy market, showcasing its differentiated capabilities in developing and producing innovative treatments.
Daewoong announced competences for stem cell therapy production to Orthopedic Surgeons, Neurologists, Internists, Aesthetic Doctors, and General Practitioners at the Annual Scientific Meeting of the Indonesian Society for Tissue Engineering and Cellular Therapy(ASM REJASELINDO), held at the Aryaduta Hotel, Jakarta, on December 6-7, 2024.
Daewoong introduced its wide range of stem cell products offered by Daewoong Biologics Indonesia and CGBio Indonesia. Daewoong Biologics Indonesia, a corporation specializing in stem cell therapy, showcased not only stem cell therapy production, such as secretome and NK(Natural Killer) cells, but also its GMP-certified production process, making it the fourth company in Indonesia to achieve this certification. CGBio Indonesia highlighted the CellUnit, a rapid Stromal Vascular Fraction (SVF) processing machine, emphasizing its time-saving and user-friendly features.
Daewoong's differentiated capabilities in stem cell technology and its exceptional manufacturing processes begin with ensuring the safety of its therapeutics. By conducting rigorous donor screenings in compliance with FDA standards, Daewoong guarantees the safety of its cell therapies. Furthermore, the company produces high-quality stem cell therapeutics through advanced manufacturing systems aligned with ISCT (International Society for Cell and Gene Therapy) guidelines. These guidelines are recognized as the global standard for the development of cell and gene therapies, offering comprehensive protocols that extend beyond production processes to ensure the safety, efficacy, and quality of therapeutics.
In addition, Daewoong has established a diverse pipeline that includes autologous stem cells derived from adipose tissue and bone marrow, allogeneic stem cells derived from umbilical cords, conditioned media, and immune cells. This robust portfolio enables Daewoong to deliver personalized treatment solutions to patients. In particular, the company has introduced technologies for producing autologous NK cells and exosomes, which are challenging to manufacture locally. By the first quarter of 2025, Daewoong plans to launch allogeneic umbilical cord-derived exosomes, further strengthening its leadership in the market.
Stem cell therapy is emerging as a promising option for managing various diseases across orthopedics, neurology, internal medicine, and dermatology.
Last September, the Indonesian Ministry of Health issued the Guidelines for the Implementation of Stem Cell Therapy Services in the Fields of Orthopedics and Traumatology, providing comprehensive guidelines for implementing stem cell therapy in these fields. Thanks to the implementation of this regulation, stem cell therapy in orthopedics and traumatology now has a regulatory framework that can serve as a standardized guideline for all medical professionals in Indonesia.
At the ASM REJASELINDO event, dr. Afriyanti Shandi, Sp.BP-RE, MARS, a distinguished plastic surgeon from Pertamina Central Hospital, delivered an insightful session on Daewoong Biologics Indonesia's comprehensive range of stem cell products. Dr. Afriyanti also highlighted CGBio's CellUnit, an advanced, fully automated technology designed to efficiently process SVF.
Dr. Afriyanti stated, "Daewoong offers a wide range of cellular therapy products, including stem cells, secretomes, and NK cells, to physicians and medical professionals. Furthermore, Daewoong's production facilities can process and cultivate cells from adipose tissue (autologous Adipose Mesenchymal Stem Cells) to support the treatment of various diseases."
"Additionally, in advancing medical technology for stem cell applications, CGBio showcased the CellUnit, a fully automated system designed to rapidly process SVF in approximately 45 minutes. This innovative device offers significant advantages, including a closed-system process to prevent bacterial and microbial contamination and a streamlined production timeline for SVF," dr. Afriyanti added.
These stem cell products and advanced technologies further reinforce Daewoong's contributions to Indonesia over the past 20 years. Daewoong continues to collaborate with Indonesian medical experts and professionals, offering cutting-edge facilities to support technology transfer and the discovery of new drugs.
Furthermore, since 2018, Daewoong has expanded its research infrastructure by opening three laboratories: the Bio Technology Research Center in 2018, the Bio Analytic Center in 2022 at the University of Indonesia, and the Daewoong Drug Delivery System Laboratory at Institut Teknologi Bandung, launched in 2024. Notably, two laboratories at the University of Indonesia have been conducting research on stem cell and biopharmaceutical treatments for Indonesia.
Baik In Hyun, Head of Daewoong Biologics Indonesia’s business unit, remarked, "Stem cell therapy represents the future of healthcare and will revolutionize the medical sector, including in Indonesia. Daewoong is committed to delivering a comprehensive portfolio of cutting-edge products and technologies to empower Indonesian experts in elevating the nation's healthcare standards."
- # # # -
